Dyadic C1 platform progress update
Analysis based on 6 articles · First reported Jul 07, 2026 · Last updated Jul 07, 2026
The announcement reinforces Dyadic's technological validation and potential for future revenue through partnerships and licensing. However, as a pre-revenue stage company, the immediate market impact is limited, with the stock likely seeing modest positive sentiment from continued progress.
Dyadic International, Inc. (Nasdaq: DYAI) announced continued progress across multiple global health collaborations validating its proprietary C1 protein production platform. The company received the full $3.1 million Gates Foundation grant, including a final payment of $738,743 in June 2026, to fund monoclonal antibody research for RSV and malaria. Studies showed C1-produced antibodies comparable to traditional CHO cell systems with higher yields and lower costs. In collaboration with CEPI and Fondazione Biotecnopolo di Siena, plasmid-to-purified-protein production was demonstrated in approximately 15 days. Dyadic also announced a collaboration with Scripps Research for Bundibugyo Ebola preparedness, expecting to deliver antigen samples by end of July 2026. The company participates in European Vaccines Hub and FBS initiatives targeting Ebola and hantavirus. Dyadic believes the C1 platform addresses biologics manufacturing bottlenecks and represents a $25 billion addressable opportunity.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard